+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 55Years +
All Genders
ID06540833

Randomized Study to Evaluate the Efficacy and Safety of Sublingual ITI-1284 for Psychosis in Alzheimers Disease

Led by Intra-Cellular Therapies, Inc. · Updated on 2026-11-03

370

Participants Needed

71

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284, a sublingual drug, compared with placebo in treating psychosis associated with Alzheimers disease. This Phase 2, multicenter, randomized, double-blind, placebo-controlled study involves adults aged 55 and older diagnosed with Alzheimers disease and psychosis. The study aims to improve understanding of how ITI-1284 may affect psychotic symptoms in this population. Participants will receive either ITI-1284 tablets at doses of 10 mg or 20 mg or matching placebo tablets, taken once daily by sublingual administration. The study uses a flexible-dose design and follows a parallel-group model with random assignment to the drug or placebo groups. Treatment and assessments are conducted over the study period, with primary measurement of psychosis symptoms at Week 6. Throughout the trial, participants will be monitored regularly for symptom changes using the BEHAVE-AD psychosis subscale and the Clinical Global Impression-Severity score. Cognitive function will be evaluated using the Mini-Mental State Examination. Safety and tolerability will be assessed continuously, and a designated caregiver will support participants. The total study duration extends through to December 2028, with primary outcomes assessed at 6 weeks.

CONDITIONS

Brief Title

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here